DOXIMITY INC-CLASS A Business Summary

Doximity Inc. (DOCS) operates the preeminent digital platform for U.S. medical professionals, primarily generating revenue through a high-margin subscription model tailored to pharmaceutical manufacturers and health systems. The company’s revenue streams are categorized into three primary segments: Marketing Solutions, which facilitates targeted clinical content delivery; Hiring Solutions, providing digital recruitment and talent sourcing for healthcare organizations; and Productivity Solutions, encompassing HIPAA-compliant telehealth, digital faxing, and advanced AI-driven tools such as DocsGPT and AI Scribe. As of March 2026, Doximity has aggressively expanded its AI capabilities following the acquisition of Pathway, integrating real-time, peer-reviewed clinical references into physician workflows. The company maintains a dominant market share, hosting over 80% of U.S. physicians, and competes directly with professional networks like Sermo, Medscape (WebMD), and Figure 1. Doximity distinguishes itself through its comprehensive suite of workflow-integrated tools, positioning it as an essential daily utility for clinicians rather than a traditional social network. Doximity was co-founded by CEO Jeff Tangney, the former President and COO of Epocrates with a background at Goldman Sachs, and Chief Strategy Officer Dr. Nate Gross, an MD and co-founder of the digital health incubator Rock Health. The executive team is further bolstered by Chief Technology Officer Jey Balachandran, who leads the platform’s engineering and AI strategy, and Siddharth Sitaram, who was appointed Chief Financial Officer in February 2026 following the medical leave of long-time CFO Anna Bryson. The leadership group is complemented by co-founder Shari Buck, who serves as Senior Vice President of People and Operations. Doximity’s board includes prominent venture capitalists such as Rebecca Lynn of Canvas Ventures, an early backer from the company’s Series B round. Other notable institutional investors include Emergence Capital and T. Rowe Price, underscoring the company's strong pedigree in scaling healthcare technology and navigating public markets while driving technological innovation in the medical sector.